Medicenna Therapeutics' Acquisition

Medicenna Therapeutics was acquired by A2 Acquisition Corp on February 06, 2017.

Medicenna is a clinical stage, privately held, immuno-oncology company developing first-in-class, Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R)…

Articles about Medicenna Therapeutics' Acquisition: